Fact CheckerSign in

NCT06646341Recruiting

EMVI as a Determinant of Metastasis in Colorectal Cancer

Source: ClinicalTrials.gov · Last updated 1 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Bowel cancer is the fourth most commonly occurring cancer and the second highest cause of cancer deaths in the UK. Despite advances in treatment, over 40% of patients will die within 5 years. This is normally due to spread of the cancer to other organs (called metastases). Much of the current research focuses on use of additional treatments such as radiotherapy and chemotherapy before or after surgery (adjuvant treatment). It is of vital importance that patients who would benefit from adjuvant treatment can be accurately identified. At the moment, the system used locally to do this places emphasis on the presence of affected lymph nodes (glands). This is because doctors believe that cancer spreads to other organs through the lymphatic system. However, recent studies have suggested that this is not the case. It is believed that cancer spreads to other organs through the blood stream rather than the lymph node system. This research will look at the genetic material in tumours and metastases as well as in areas of blood vessel invasion and lymph nodes. The analysis will allow us to build a 'family tree' of the tumour and allow us to map the pathway by which the tumour spreads. Tissue samples already collected through a patient's routine care will be used for this study. If the spread through the blood vessels is proven, this would change the way in which patients are selected for treatment and allow development of new treatments to target these pathways.

Status (registry)
Recruiting
Study type
Observational
Enrollment
100 (estimated)
First submitted
15 Oct 2024
Start date
1 Jan 2023
Primary completion date
31 Dec 2025
Lead sponsor
Imperial College London
NCT number
NCT06646341

What you commit to

  • Study type: Observational
  • Planned participants: 100
  • From 1 Jan 2023 to the primary completion date, 31 Dec 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Local resection of the primary tumour

Other

  • Pathological complete response in the primary tumour
  • Inadequate quantity of tissue sample to perform analyses

Who the study is looking for

  • Are aged 16 years or over with colorectal cancer
  • Colon / rectum has been surgically removed
  • Distant metastases has been surgically removed
  • Pre operative staging in the form of CT/MRI has been undertaken and images available for review

Age in the registry: 16 years to 100 years · Sex: All

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Hampshire Hospitals Nhs Foundation Trust
Coordinator of this site? Confirm its status
BasingstokeUnited KingdomRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.